

# Lucia Lopalco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9006136/publications.pdf>

Version: 2024-02-01

95  
papers

4,724  
citations

109264

35  
h-index

102432

66  
g-index

96  
all docs

96  
docs citations

96  
times ranked

4561  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Control of HIV despite the Discontinuation of Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 1999, 340, 1683-1683.  | 13.9 | 305       |
| 2  | Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges. <i>Immunity</i> , 2011, 34, 269-280.  | 6.6  | 276       |
| 3  | Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. <i>Blood</i> , 2006, 108, 1580-1587.   | 0.6  | 255       |
| 4  | Mucosal and Plasma IgA from HIV-1-Exposed Uninfected Individuals Inhibit HIV-1 Transcytosis Across Human Epithelial Cells. <i>Journal of Immunology</i> , 2000, 165, 5170-5176.   | 0.4  | 239       |
| 5  | Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. <i>Aids</i> , 2000, 14, 1917-1920.   | 1.0  | 174       |
| 6  | HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection: an IgA gene and functional analysis. <i>Mucosal Immunology</i> , 2009, 2, 412-426. | 2.7  | 140       |
| 7  | Human Immunodeficiency Virus (HIV)â€“Specific IgA and HIV Neutralizing Activity in the Serum of Exposed Seronegative Partners of HIVâ€“Seropositive Persons. <i>Journal of Infectious Diseases</i> , 1999, 180, 871-875.  | 1.9  | 135       |
| 8  | Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. <i>Aids</i> , 2005, 19, 1947-1955.  | 1.0  | 132       |
| 9  | Cross-Clade HIV-1â€“Specific Neutralizing IgA in Mucosal and Systemic Compartments of HIV-1â€“Exposed, Persistently Seronegative Subjects. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 30, 413-420.                                       | 0.9  | 118       |
| 10 | Isotype modulates epitope specificity, affinity, and antiviral activities of antiâ€“HIV-1 human broadly neutralizing 2F5 antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12680-12685.                 | 3.3  | 115       |
| 11 | CCR5-Reactive Antibodies in Seronegative Partners of HIV-Seropositive Individuals Down-Modulate Surface CCR5 In Vivo and Neutralize the Infectivity of R5 Strains of HIV-1 In Vitro. <i>Journal of Immunology</i> , 2000, 164, 3426-3433.                           | 0.4  | 114       |
| 12 | Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. <i>Aids</i> , 2000, 14, 2083-2092.   | 1.0  | 112       |
| 13 | Human immunodeficiency virus type 1 gp120 mimics a hidden monomorphic epitope borne by class I major histocompatibility complex heavy chains.. <i>Journal of Experimental Medicine</i> , 1991, 174, 53-62.  | 4.2  | 109       |
| 14 | CCR5: From Natural Resistance to a New Anti-HIV Strategy. <i>Viruses</i> , 2010, 2, 574-600.  | 1.5  | 108       |
| 15 | The â€“immunologic advantageâ€™ of HIV-exposed seronegative individuals. <i>Aids</i> , 2009, 23, 161-175.   | 1.0  | 106       |
| 16 | Conserved Structural Features in the Interaction Between Retroviral Surface and Transmembrane Glycoproteins?. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 1571-1580.   | 0.5  | 105       |
| 17 | Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. <i>Aids</i> , 2001, 15, 431-432.  | 1.0  | 95        |
| 18 | Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. <i>Frontiers in Immunology</i> , 2020, 11, 1049.   | 2.2  | 88        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Apolipoprotein B mRNAâ€‘Editing Enzyme, Catalytic Polypeptideâ€‘Like 3G: A Possible Role in the Resistance to HIV of HIVâ€‘Exposed Seronegative Individuals. <i>Journal of Infectious Diseases</i> , 2007, 195, 960-964.               | 1.9 | 87        |
| 20 | Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. <i>Blood</i> , 2012, 119, 6259-6267.   | 0.6 | 83        |
| 21 | Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4869-4886.  | 2.4 | 81        |
| 22 | Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. <i>Aids</i> , 2003, 17, 531-539.  | 1.0 | 80        |
| 23 | Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the I±-helix of gp41. <i>Aids</i> , 2002, 16, 1731-1741.  | 1.0 | 75        |
| 24 | Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. <i>PLoS ONE</i> , 2013, 8, e55438.  | 1.1 | 69        |
| 25 | Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. <i>Blood</i> , 2006, 107, 4825-4833.  | 0.6 | 66        |
| 26 | Human immunodeficiency virus type 1 gp120 C5 region mimics the HLA class I I±1 peptide-binding domain. <i>European Journal of Immunology</i> , 1993, 23, 2016-2021.  | 1.6 | 62        |
| 27 | Immunological Profile of Heterosexual Highly HIVâ€‘Exposed Uninfected Individuals: Predominant Role of CD4 and CD8 Tâ€‘Cell Activation. <i>Journal of Infectious Diseases</i> , 2007, 196, 1191-1201.                                  | 1.9 | 46        |
| 28 | Scarcity or Absence of Humoral Immune Responses in the Plasma and Cervicovaginal Lavage Fluids of Heavily HIV-1-Exposed But Persistently Seronegative Women. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 469-486.          | 0.5 | 46        |
| 29 | A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions. <i>Aids</i> , 2003, 17, 43-51.  | 1.0 | 45        |
| 30 | Anti-Cell Antibodies in Exposed Seronegative Individuals with HIV Type 1-Neutralizing Activity. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 109-115.   | 0.5 | 42        |
| 31 | Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. <i>Journal of General Virology</i> , 2005, 86, 339-348.                | 1.3 | 42        |
| 32 | Upregulation of Interferon-?? and RANTES in the Cervix of HIV-1-Seronegative Women With High-Risk Behavior. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 137-143.   | 0.9 | 40        |
| 33 | SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naÃ±ve and previously COVID-19-infected individuals. <i>EBioMedicine</i> , 2022, 77, 103888.   | 2.7 | 39        |
| 34 | HIV-Specific Antibodies But Not T-Cell Responses Are Associated With Protection in Seronegative Partners of HIV-1-Infected Individuals in Cambodia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 412-419. | 0.9 | 38        |
| 35 | Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. <i>Vaccine</i> , 2011, 29, 4903-4912.   | 1.7 | 38        |
| 36 | CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. <i>Blood</i> , 2004, 104, 2205-2206.  | 0.6 | 37        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Identification of Human Immunodeficiency Virus Type 1 Glycoprotein gp120/gp41 Interacting Sites by the Idiotypic Mimicry of Two Monoclonal Antibodies. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 33-39.           | 0.5 | 36        |
| 38 | Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. <i>Aids</i> , 2007, 21, 13-22.  | 1.0 | 36        |
| 39 | Human Antibodies to Immunodominant C5 Region of HIV-1 gp120 Cross-React with HLA Class I on Activated Cells. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 157-162.  | 0.5 | 34        |
| 40 | High-efficiency antibody discovery achieved with multiplexed microscopy. <i>Microscopy (Oxford)</i> , 2010, 10, 10-11.   | 0.7 | 34        |
| 41 | Abundant and Superficial Expression of C-Type Lectin Receptors in Ectocervix of Women at Risk of HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 239-247.                             | 0.9 | 33        |
| 42 | The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection. <i>Frontiers in Immunology</i> , 2017, 8, 1358.  | 2.2 | 33        |
| 43 | Passively Transmitted gp41 Antibodies in Babies Born from HIV-1 Subtype C-Seropositive Women: Correlation between Fine Specificity and Protection. <i>Journal of Virology</i> , 2012, 86, 4129-4138.                           | 1.5 | 32        |
| 44 | Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. <i>Virology</i> , 2012, 431, 1-11.  | 1.1 | 32        |
| 45 | Frequency and phenotype of B cell subpopulations in young and aged HIV-1 infected patients receiving ART. <i>Retrovirology</i> , 2014, 11, 76.   | 0.9 | 32        |
| 46 | Cross-Reactive Response to Human Immunodeficiency Virus Type 1 (HIV-1) gp120 and HLA Class I Heavy Chains Induced by Receipt of HIV-1-Derived Envelope Vaccines. <i>Journal of Infectious Diseases</i> , 1993, 168, 1396-1403. | 1.9 | 30        |
| 47 | Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. <i>HIV Clinical Trials</i> , 2002, 3, 115-124.   | 2.0 | 30        |
| 48 | Induction of Murine Mucosal CCR5-Reactive Antibodies as an Anti-Human Immunodeficiency Virus Strategy. <i>Journal of Virology</i> , 2005, 79, 6848-6858.   | 1.5 | 30        |
| 49 | Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. <i>Retrovirology</i> , 2013, 10, 71.   | 0.9 | 30        |
| 50 | Autoantibodies to CD4 in HIV Type 1-Exposed Seronegative Individuals. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 273-280.   | 0.5 | 29        |
| 51 | HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection. <i>Immunology Letters</i> , 1996, 51, 39-43.  | 1.1 | 28        |
| 52 | Non-cytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected individuals. <i>Aids</i> , 2002, 16, 1003-1008.   | 1.0 | 26        |
| 53 | Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection. <i>Immunology</i> , 2007, 123, 070720050330001-???                      | 2.0 | 26        |
| 54 | Calcitonin gene-related peptide inhibits Langerhans cell-mediated HIV-1 transmission. <i>Journal of Experimental Medicine</i> , 2013, 210, 2161-2170.  | 4.2 | 25        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?. <i>Molecules</i> , 2020, 25, 5888.   | 1.7 | 25        |
| 56 | Humoral Immunity in HIV-1 Exposure: Cause or Effect of HIV Resistance?. <i>Current HIV Research</i> , 2004, 2, 127-139.   | 0.2 | 24        |
| 57 | Is Autoimmunity a Component of Natural Immunity to HIV?. <i>Current HIV Research</i> , 2006, 4, 177-190.  | 0.2 | 23        |
| 58 | Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load. <i>Aids</i> , 2010, 24, 35-43.  | 1.0 | 23        |
| 59 | HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2000, 14, 15-21.  | 0.7 | 23        |
| 60 | Role of CD4 and CCR5 Levels in the Susceptibility of Primary Macrophages to Infection by CCR5-Dependent HIV Type 1 Isolates. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 983-987.   | 0.5 | 22        |
| 61 | Anti-CD4 Antibodies in Exposed Seronegative Adults and in Newborns of HIV Type 1-Seropositive Mothers: A Follow-up Study. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1079-1085.  | 0.5 | 21        |
| 62 | Two Amino Acid Substitutions within the First External Loop of CCR5 Induce Human Immunodeficiency Virus-Blocking Antibodies in Mice and Chickens. <i>Journal of Virology</i> , 2008, 82, 4125-4134.   | 1.5 | 19        |
| 63 | Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve. <i>Communications Medicine</i> , 2021, 1, .  | 1.9 | 18        |
| 64 | The role of IL-1 $\beta$ in reduced IL-7 production by stromal and epithelial cells: a model for impaired T cell numbers in the gut during HIV-1 infection. <i>Journal of Internal Medicine</i> , 2010, 268, 181-193.                           | 2.7 | 15        |
| 65 | Natural anti-CCR5 antibodies in HIV-infection and -exposure. <i>Journal of Translational Medicine</i> , 2011, 9, S4.  | 1.8 | 15        |
| 66 | Human Immunodeficiency Virus Type 1 Glycoprotein 120-Specific T Lymphocytes Provide Intermolecular Help for Anti-CD4 Autoantibody Production in Exposed Uninfected Subjects. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 1461-1469. | 0.5 | 14        |
| 67 | Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones. <i>Journal of Translational Medicine</i> , 2014, 12, 346.   | 1.8 | 14        |
| 68 | Setting of Methods for Analysis of Mucosal Antibodies in Seminal and Vaginal Fluids of HIV Seropositive Subjects from Cambodian and Italian Cohorts. <i>PLoS ONE</i> , 2010, 5, e9920.  | 1.1 | 13        |
| 69 | Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms. <i>Journal of Translational Medicine</i> , 2014, 12, 335.                                      | 1.8 | 13        |
| 70 | Relationship between serum IL-7 concentrations and lymphopenia upon different levels of HIV immune control. <i>Aids</i> , 2007, 21, 1048-1050.  | 1.0 | 12        |
| 71 | Induction of HIV-Blocking Anti-CCR5 IgA in Peyer's Patches without Histopathological Alterations. <i>Journal of Virology</i> , 2014, 88, 3623-3635.   | 1.5 | 12        |
| 72 | ERK1-Based Pathway as a New Selective Mechanism To Modulate CCR5 with Natural Antibodies. <i>Journal of Immunology</i> , 2015, 195, 3045-3057.  | 0.4 | 12        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Class B $\beta$ 2-arrestin2-dependent CCR5 signalosome retention with natural antibodies to CCR5. <i>Scientific Reports</i> , 2016, 6, 39382.   | 1.6 | 12        |
| 74 | M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. <i>Scientific Reports</i> , 2017, 7, 41018.   | 1.6 | 9         |
| 75 | A Nonparametric Procedure for Defining a New Humoral Immunologic Profile in a Pilot Study on HIV Infected Patients. <i>PLoS ONE</i> , 2013, 8, e58768.  | 1.1 | 9         |
| 76 | Protecting the initial site of viral entry: an alternative HIV vaccine target. <i>Expert Review of Vaccines</i> , 2011, 10, 1253-1256.  | 2.0 | 7         |
| 77 | Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. <i>Vaccines</i> , 2020, 8, 41.  | 2.1 | 7         |
| 78 | Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4. <i>PLoS ONE</i> , 2011, 6, e22081.   | 1.1 | 6         |
| 79 | The Abrogation of Phosphorylation Plays a Relevant Role in the CCR5 Signalosome Formation with Natural Antibodies to CCR5. <i>Viruses</i> , 2018, 10, 9.  | 1.5 | 6         |
| 80 | Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. <i>Journal of Translational Medicine</i> , 2009, 7, 101.  | 1.8 | 5         |
| 81 | HLA-C is necessary for optimal human immunodeficiency virus type 1 infection of human peripheral blood CD4 lymphocytes. <i>Journal of General Virology</i> , 2010, 91, 235-241.                                       | 1.3 | 5         |
| 82 | GM-3 Lactone Mimetic Interacts with CD4 and HIV-1 Env Proteins, Hampering HIV-1 Infection without Inducing a Histopathological Alteration. <i>ACS Infectious Diseases</i> , 2016, 2, 564-571.                         | 1.8 | 5         |
| 83 | Dysfunctions in the migratory phenotype and properties of circulating immature transitional B cells during HIV-1 infection. <i>Aids</i> , 2016, 30, 2169-2177.  | 1.0 | 5         |
| 84 | Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity. <i>MedChemComm</i> , 2017, 8, 422-433.  | 3.5 | 5         |
| 85 | HIV-1 and the self-nonsel self connection: how to sleep with the enemy and be much better off. <i>AIDS Reviews</i> , 2008, 10, 162-71.  | 0.5 | 4         |
| 86 | Native CGRP Neuropeptide and Its Stable Analogue SAX, But Not CGRP Peptide Fragments, Inhibit Mucosal HIV-1 Transmission. <i>Frontiers in Immunology</i> , 2021, 12, 785072.  | 2.2 | 4         |
| 87 | Modeling and Spectroscopic Studies of Synthetic Diazabicyclo Analogs of the HIV-1 Inhibitor BMS-78806 and Evaluation of Their Antiviral Activity. <i>European Journal of Organic Chemistry</i> , 2011, 2011, 287-294. | 1.2 | 3         |
| 88 | Short Communication: Decreased Plasma Calcitonin Gene-Related Peptide as a Novel Biomarker for HIV-1 Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 52-55.                              | 0.5 | 3         |
| 89 | Autoantibodies against beta 2-microglobulin-free HLA antigens in AIDS patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1993, 6, 1114-9.   | 1.0 | 3         |
| 90 | Title is missing!. <i>Retrovirology</i> , 2006, 3, P36.   | 0.9 | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 91 | Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.   | 6.0 | 2         |
| 92 | Induction of Antihuman CCR5 Chemokine Receptor Type 5 Antibodies by a Bovine Herpesvirus Type-4 Based Vector. Frontiers in Immunology, 2017, 8, 1402. | 2.2 | 2         |
| 93 | Studies on propylamine transfer activity in anti-AdoDATO antibodies. Amino Acids, 1997, 12, 299-308.  | 1.2 | 1         |
| 94 | Tackling HIV: Genetic vs. Immune CCR5 targeting. Journal of AIDS & Clinical Research, 2014, 05, .   | 0.5 | 1         |
| 95 | Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection. Cells, 2022, 11, 77.  | 1.8 | 1         |